Marking its 10th anniversary, the Cambridge-based Food Allergy Science Initiative (FASI) has launched the Food Allergy Medicines Accelerator (FAMA). Backed by an initial $10 million investment, this philanthropic endeavor aims to bridge the gap between basic academic discoveries and clinical treatments for the millions of people worldwide living with food allergies.
Originally founded in 2016 at the Broad Institute of MIT and Harvard, FASI now operates as an independent nonprofit that unites more than 100 researchers across over 20 leading laboratories—including teams at Harvard Medical School, Yale School of Medicine, Boston Children’s Hospital, and Mass General Brigham. To date, the organization has deployed more than $50 million across 126 research grants, helping reframe food allergy not simply as a localized reaction, but as a complex, whole-body, systems-level disorder.
A decade of cross-disciplinary inquiry combining immunology, neuroscience, microbiology, gastroenterology, and computational biology has uncovered critical mechanisms governing allergic reactions. Among its key milestones, FASI-backed research revealed that the immune system directly signals the brain to prompt food avoidance behavior, demonstrated that damaged skin barriers can sensitize individuals to food allergens elsewhere in the body, and showed that specialized neurons and antibodies can actively suppress or amplify allergic responses.
The newly established Food Allergy Medicines Accelerator is designed to leverage these scientific breakthroughs by pairing academic investigation with experienced industry drug developers, dedicated drug-development infrastructure, and external partners. By bringing drug-development expertise and industry-level rigor into the academic discovery process, FAMA seeks to de-risk promising early-stage targets and determine more quickly which have the potential to become new treatments.
FAMA’s initial $10 million investment is funding four early-stage drug discovery programs spanning a range of therapeutic approaches. The initiative will focus on validating potential drug targets, determining whether they can be effectively modulated, and developing the assays and tools needed to identify and evaluate potential therapeutic candidates.
Reflecting on the progress made since the organization’s inception, Dr Carlos Bosques, Chief Executive Officer of FASI, underscored the shift from defensive management to targeted therapeutics:
A decade ago, a food allergy diagnosis meant a lifetime of avoidance and fear of the next reaction. Today, we understand the biology of this disease at a level that once seemed out of reach and that progress has created an opportunity to change what comes next. The Food Allergy Medicines Accelerator is designed to build on that foundation by moving the most promising FASI discoveries toward new therapeutic opportunities. We look forward to partnering with biopharma to translate these insights into medicines that can make a meaningful difference for patients.
Programs that show sufficient promise could ultimately transition beyond FAMA into clinical development, either through the formation of new biotechnology companies or partnerships with established industry organizations. Emphasizing the vital role of early funding in driving high-risk translational work, Dr Christine Olsen, Co-Founder and Executive Chair of the FASI Board of Directors, noted:
Philanthropy is what changes the pace of progress in a field like this. It advances discovery to the point where a biotech or pharmaceutical partner can see its potential for possible partnership. Alongside our continued commitment to foundational research, the Food Allergy Medicines Accelerator will extend our efforts in the direction of the clinic, and toward help for families who are counting on us to unlock treatments and cures.
